Discrimination of agonist and antagonist forms of CXCL10 in biological samples
- 1 December 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 167 (1), 137-148
- https://doi.org/10.1111/j.1365-2249.2011.04488.x
Abstract
Summary: The ready access to commercially available multiplex assays and the importance of inflammation in disease pathogenesis has resulted in an abundance of studies aimed at identifying surrogate biomarkers for different clinically important questions. Establishing a link between a biomarker and disease pathogenesis, however, is quite complex, and in some instances this complexity is compounded by post-translational modifications and the use of immunoassays that do not always discriminate between the different forms of the same protein. Herein, we provide a detailed description of an assay system that has been established to discriminate the agonist form of CXCL10 from the NH2-terminal truncated form of the molecule generated by dipeptidylpeptidase IV (DPP4) cleavage. We demonstrate the utility of this assay system for monitoring agonist and antagonist forms of CXCL10 in culture supernatant, patient plasma and urine samples. Given the important role of CXCL10 in chronic inflammatory diseases and its suggested role as a predictive marker in managing patients with chronic hepatitis C, asthma, atopic dermatitis, transplantation, tuberculosis, kidney injury, cancer and other diseases, we believe that our method will be of general interest to the research and medical community.Keywords
This publication has 73 references indexed in Scilit:
- CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implicationsCytokine & Growth Factor Reviews, 2011
- Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCVJCI Insight, 2011
- Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseJournal of Hepatology, 2010
- CXC-Chemokine Ligand 10 in Idiopathic Pulmonary Arterial Hypertension: Marker of Improved SurvivalLung, 2010
- Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistenceJCI Insight, 2009
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell RecruitmentCancer Research, 2009
- Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in IndiaMalaria Journal, 2008
- Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malariaProceedings of the National Academy of Sciences of the United States of America, 2008
- Mycobacterium bovis bacillus Calmette–Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivoClinical and Experimental Immunology, 2006
- Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNature Biotechnology, 2006